Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers

Radiation Research

Volumn 167, Issue 2, 2007, Pages 127-145

  Ljungkvist, Anna S E ^a   Bussink, Johan ^a   Kaanders, Johannes H A M ^a   Van Der Kogel, Albert J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,1,1,3,3,3 HEXAFLUORO 2 PROPOXY) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MISONIDAZOLE; PIMONIDAZOLE;

CANCER RADIOTHERAPY; HUMAN; HYPOXEMIA; HYPOXIC CELL; MACROMOLECULE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; OXYGEN TISSUE LEVEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CARCINOMA, MUCOEPIDERMOID; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASMS; OXYGEN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846850493     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR0719.1     Document Type: Review

References (215)

1. P. Vaupel, Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14, 198-206 (2004).
2. Q. T. Le, N. C. Denko and A. J. Giaccia, Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23, 293-310 (2004).
3. M. Höckel and P. Vaupel, Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276 (2001).
4. E. K. Rofstad, Microenvironment-induced cancer metastasis. Int. J. Radiat. Biol. 76, 589-605 (2000).
5. A. L. Harris, Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47 (2002).
6. D. M. Brizel, S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz and M. W. Dewhirst, Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56, 941-943 (1996).
7. J. C. Mottram, A factor of importance in the radiosensitivity of tumours. Br. J. Radiol. 9, 606-614 (1936).
8. L. Gray, A. D. Conger, M. Ebert, S. Hornsey and O. C. A. Scott, The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 28, 638-648 (1953).
9. D. M. Brizel, G. S. Sibley, L. R. Prosnitz, R. L. Scher and M. W. Dewhirst, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285-289 (1997).
10. A. Fyles, M. Milosevic, D. Hedley, M. Pintilie, W. Levin, L. Manchul and R. P. Hill, Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 20, 680-687 (2002).
11. M. Höckel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer and P. Vaupel, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515 (1996).
12. J. H. A. M. Kaanders, K. I. E. M. Wijffels, H. A. M. Marres, A. S. E. Ljungkvist, L. A. M. Pop, F. J. A. van den Hoogen, P. C. M. de Wilde, J. Bussink, J. A. Raleigh and A. J. van der Kogel, Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62, 7066-7074 (2002).
13. J. Overgaard, H. S. Hansen, M. Overgaard, L. Bastholt, A. Berthelsen, L. Specht, B. Lindelov and K. Jorgensen, A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol. 46, 135-146 (1998).
14. D. J. Chaplin, M. R. Horsman and M. J. Trotter, Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J. Natl. Cancer Inst. 82, 672-676 (1990).
15. J. M. Henk and C. W. Smith, Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet 2, 104-105 (1977).
16. J. H. A. M. Kaanders, L. A. M. Pop, H. A. M. Marres, J. Liefers, F. J. van den Hoogen, W. A. van Daal and A. J. van der Kogel, Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother. Oncol. 48, 115-122 (1998).
17. R. Mayer, M. R. Hamilton-Farrell, A. J. van der Kleij, J. Schmutz, G. Granstrom, Z. Sicko, Y. Melamed, U. M. Carl, K. A. Hartmann and P. Sminia, Hyperbaric oxygen and radiotherapy. Strahlenther. Onkol. 181, 113-123 (2005).
18. Y. Shi, C. S. Lee, J. Wu, C. J. Koch, S. R. Thom, A. Maity and E. J. Bernhard, Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature. Head Neck 27, 362-369 (2005).
19. A. Rosenberg and S. Knox, Radiation sensitization with redox modulators: A promising approach. Int. J. Radiat. Oncol. Biol. Phys. 64, 343-354 (2006).
20. E. M. Zeman, J. M. Brown, M. J. Lemmon, V. K. Hirst and W. W. Lee, SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12, 1239-1242 (1986).
21. J. Overgaard and M. R. Horsman, Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiat. Oncol. 6, 10-21 (1996).
22. I. F. Tannock, The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br. J. Cancer 22, 258-273 (1968).
23. D. G. Hirst and J. Denekamp, Tumour cell proliferation in relation to the vasculature. Cell. Tissue. Kinet. 12, 31-42 (1979).
24. J. Bussink, J. H. A. M. Kaanders, P. F. J. W. Rijken, C. A. Martindale and A. J. van der Kogel, Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. Br. J. Cancer 77, 57-64 (1998).
25. A. S. E. Ljungkvist, J. Bussink, P. F. J. W. Rijken, J. H. A. M. Kaanders, A. J. van der Kogel and J. Denekamp, Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 54, 215-228 (2002).
26. M. A. Konerding, C. van Ackern, E. Fait, F. Steinberg and C. Streffer, Morphological aspects of tumor angiogenseis and microcirculation. In Blood Perfusion and Micro environmnet of Human Tumors (M. Molls and P. Vaupel, Eds.), pp. 6-17. Springer Verlag, Berlin and Heidelberg, 1998.
27. H. J. J. A. Bernsen, P. F. J. W. Rijken, T. Oostendorp and A. J. van der Kogel, Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br. J. Cancer 71, 721-726 (1995).
28. N. Weidner, J. P. Semple, W. R. Welch and J. Folkman, Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1-8 (1991).
29. J. Bussink, J. H. Kaanders and A. J. van der Kogel, Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother. Oncol. 67, 3-15 (2003).
30. R. H. Thomlinson and L. H. Gray, The histological structure of some human lung cancers and the possibie implications for radiotherapy. Br. J. Cancer IX, 539-549 (1955).
31. J. M. Cline, D. E. Thrall, G. L. Rosner and J. A. Raleigh, Distribution of the hypoxia marker CCI-103F in canine tumors. Int. J. Radiat. Oncol. Biol. Phys. 28, 921-933 (1994).
32. P. Vaupel, F. Kallinowski and P. Okunieff, Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465 (1989).
33. K. I. E. M. Wijffels, J. H. A. M. Kaanders, P. F. J. W. Rijken, J. Bussink, F. J. van den Hoogen, H. A. M. Marres, P. C. M. de Wilde, J. A. Raleigh and A. J. van der Kogel, Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br. J. Cancer 83, 674-683 (2000).
34. S. M. Evans, S. M. Hahn, D. P. Magarelli and C. J. Koch, Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am. J. Clin. Oncol. 24, 467-472 (2001).
35. E. M. Zeman, D. P. Calkins, J. M. Cline, D. E. Thrall and J. A. Raleigh, The relationship between proliferative and oxygenation status in spontaneous canine tumors. Int. J. Radiat. Oncol. Biol. Phys. 27, 891-898 (1993).
36. H. S. Reinhold, B. Blachiwiecz and A. Blok, Oxygenation and reoxygenation in "sandwich" tumours. Bibl. Anat. 15, 270-272 (1977).
37. J. M. Brown, Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 52, 650-656 (1979).
38. M. J. Trotter, D. J. Chaplin, R. E. Durand and P. L. Olive, The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 16, 931-934 (1989).
39. R. E. Durand and N. E. LePard, Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol. 34, 317-323 (1995).
40. R. E. Durand and N. E. LePard, Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother. Oncol. 42, 171-179 (1997).
41. D. J. Chaplin, R. E. Durand and P. L. Olive, Acute hypoxia in tumors: Implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys. 12, 1279-1282 (1986).
42. M. W. Dewhirst, H. Kimura, S. W. Rehmus, R. D. Braun, D. Papahadjopoulos, K. Hong and T. W. Secomb, Microvascular studies on the origins of perfusion-limited hypoxia. Br. J. Cancer 27 (Suppl.), S247-S251 (1996).
43. 2 gradients in window chamber tumours: impact on tumour hypoxia. Br. J. Cancer 79, 1717-1722 (1999).
44. S. Walenta, S. Snyder, Z. A. Haroon, R. D. Braun, K. Amin, D. Brizel, W. Mueller-Klieser, B. Chance and M. W. Dewhirst, Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int. J. Radiat. Oncol. Biol. Phys. 51, 840-848 (2001).
45. B. G. Wouters, S. A. Weppler, M. Koritzinsky, W. Landuyt, S. Nuyts, J. Theys, R. K. Chiu and P. Lambin, Hypoxia as a target for combined modality treatments. Eur. J. Cancer 38, 240-257 (2002).
46. M. Milosevic, A. Fyles, D. Hedley and R. Hill, The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 14, 249-258 (2004).
47. D. M. Brizel, R. K. Dodge, R. W. Clough and M. W. Dewhirst, Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53, 113-117 (1999).
48. M. Nordsmark, S. M. Bentzen, V. Rudat, D. Brizel, E. Lartigau, P. Stadler, A. Becker, M. Adam, M. Molls and J. Overgaard, Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77, 18-24 (2005).
49. S. M. Evans, D. Fraker, S. M. Hahn, K. Gleason, W. T. Jenkins, K. Jenkins, W. T. Hwang, P. Zhang, R. Mick and C. J. Koch, EF5 binding and clinical outcome in human soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 64, 922-927 (2006).
50. P. L. Olive, J. P. Banath and C. Aquino-Parsons, Measuring hypoxia in solid tumours-is there a gold standard? Acta Oncol. 40, 917-923 (2001).
51. J. Bussink, J. H. A. M. Kaanders and A. J. van der Kogel, Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother. Oncol. 67, 3-15 (2003).
52. J. A. Raleigh, M. W. Dewhirst and D. E. Thrall, Measuring tumor hypoxia. Semin. Radiat. Oncol. 6, 37-45 (1996).
53. P. L. Olive and R. E. Durand, Detection of hypoxic cells in a murine tumor with the use of the comet assay. J. Natl. Cancer Inst. 84, 707-711 (1992).
54. J. E. Moulder and S. Rockwell, Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 10, 695-712 (1984).
55. M. R. Horsman, A. A. Khalil, D. W. Siemann, C. Grau, S. A. Hill, E. M. Lynch, D. J. Chaplin and J. Overgaard, Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 29, 439-442 (1994).
56. I. Papandreou, A. Powell, A. L. Lim and N. Denko, Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat. Res. 569, 87-100 (2005).
57. R. A. Gatenby, H. B. Kessler, J. S. Rosenblum, L. R. Coia, P. J. Moldofsky, W. H. Hartz and G. J. Broder, Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14, 831-838 (1988).
58. 2 tension measurements. Cancer Res. 51, 3316-3322 (1991).
59. J. Bussink, J. H. A. M. Kaanders, A. M. Strik and A. J. van der Kogel, Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescence-based fiber optic probes. Radiother. Oncol. 57, 21-30 (2000).
60. 2 fluctuations in human melanoma xenografts. Int. J. Radiat. Oncol. Biol. Phys. 58, 403-409 (2004).
61. D. R. Collingridge, W. K. Young, B. Vojnovic, P. Wardman, E. M. Lynch, S. A. Hill and D. J. Chaplin, Measurement of tumor oxygenation: A comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat. Res. 147, 329-334 (1997).
62. B. M. Seddon, D. J. Honess, B. Vojnovic, G. M. Tozer and P. Workman, Measurement of tumor oxygenation: In vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat. Res. 155, 837-846 (2001).
63. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26, 45-50 (1993).
64. W. K. Young, B. Vojnovic and P. Wardman, Measurement of oxygen tension in tumours by time-resolved fluorescence. Br. J. Cancer 27 (Suppl.), S256-S259 (1996).
65. J. Bussink, J. H. A. M. Kaanders, A. M. Strik, B. Vojnovic and A. J. van der Kogel, Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines. Radiat. Res. 154, 547-555 (2000).
66. T. Jarm, G. Sersa and D. Miklavcic, Oxygenation and blood flow in tumors treated with hydralazine: Evaluation with a novel luminescence-based fiber-optic sensor. Technol. Health Care 10, 363-380 (2002).
67. S. M. Evans, K. D. Judy, I. Dunphy, W. T. Jenkins, P. T. Nelson, R. Collins, E. P. Wileyto, K. Jenkins, S. M. Hahn and C. J. Koch, Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 64, 1886-1892 (2004).
68. S. S. Foo, D. F. Abbott, N. Lawrentschuk and A. M. Scott, Functional imaging of intratumoral hypoxia. Mol. Imaging Biol. 6, 291-305 (2004).
69. B. Gallez, C. Baudelet and B. F. Jordan, Assessment of tumor oxygenation by electron paramagnetic resonance: Principles and applications. NMR Biomed. 17, 240-262 (2004).
70. F. Goda, J. A. O'Hara, E. S. Rhodes, K. J. Liu, J. F. Dunn, G. Bacic and H. M. Swartz, Changes of oxygen tension in experimental tumors after a single dose of X-ray irradiation. Cancer Res. 55, 2249-2252 (1995).
71. 19F magnetic resonance spectroscopy. Int. J. Radiat. Biol. 58, 1025-1034 (1990).
72. 19F magnetic resonance spectroscopy and immunohistochemistry. Radiat. Res. 129, 71-78 (1992).
73. S. P. Robinson, F. A. Howe, M. Stubbs and J. R. Griffiths, Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels. Br. J. Cancer 82, 2007-2014 (2000).
74. R. P. Mason, P. P. Antich, E. E. Babcock, A. Constantinescu, P. Peschke and E. W. Hahn, Non-invasive determination of tumor oxygen tension and local variation with growth. Int. J. Radiat. Oncol. Biol. Phys. 29, 95-103 (1994).
75. W. Landuyt, R. Hermans, H. Bosmans, S. Sunaert, E. Beatse, D. Farina, M. Meijerink, H. Zhang, W. van Den Bogaert and G. Marchal, BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echo-planar imaging at 1.5 T. Eur. Radiol. 11, 2332-2340 (2001).
76. J. F. Dunn, J. A. O'Hara, Y. Zaim-Wadghiri, H. Lei, M. E. Meyerand, O. Y. Grinberg, H. Hou, P. J. Hoopes, E. Demidenko and H. M. Swartz, Changes in oxygenation of intracranial tumors with carbogen: A BOLD MRI and EPR oximetry study. J. Magn. Reson. Imaging 16, 511-521 (2002).
77. B. B. Williams, H. al Hallaq, G. V. Chandramouli, E. D. Barth, J. N. Rivers, M. Lewis, V. E. Galtsev, G. S. Karczmar and H. J. Halpern, Imaging spin probe distribution in the tumor of a living mouse with 250 MHz EPR: Correlation with BOLD MRI. Magn. Reson. Imaging 47, 634-638 (2002).
78. B. F. Jordan, P. Misson, R. Demeure, C. Baudelet, N. Beghein and B. Gallez, Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: Monitoring by EPR and MRI. Int. J. Radiat. Oncol. Biol. Phys. 48, 565-570 (2000).
79. P. Mahy, M. De Bast, B. Gallez, J. Gueulette, C. J. Koch, P. Scalliet and V. Gregoire, In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother. Oncol. 67, 53-61 (2003).
80. N. M. Mazure, M. C. Brahimi-Horn, M. A. Berta, E. Benizri, R. L. Bilton, F. Dayan, A. Ginouves, E. Berra and J. Pouyssegur, HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem. Pharmacol. 68, 971-980 (2004).
81. H. Pilch, K. Schlenger, E. Steiner, P. Brockerhoff, P. Knapstein and P. Vaupel, Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int. J. Gynecol. Cancer 11, 137-142 (2001).
82. R. S. Kerbel, A. Viloria Petit, F. Okada and J. Rak, Establishing a link between oncogenes and tumor angiogenesis. Mol. Med. 4, 286-295 (1998).
83. M. Höckel and P. Vaupel, Biological consequences of tumor hypoxia. Semin. Oncol. 28 (Suppl. 8), 36-41 (2001).
84. P. H. Maxwell, HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle 3, 156-159 (2004).
85. P. Vaupel, The role of hypoxia-induced factors in tumor progression. Oncologist 9 (Suppl. 5), 10-17 (2004).
86. G. L. Semenza, Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35, 71-103 (2000).
87. G. L. Semenza, Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
88. C. W. Pugh and P. J. Ratcliffe, Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684 (2003).
89. P. Carmeliet, Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch and E. Keshet, Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
90. C. C. Wykoff, N. J. P. Beasley, P. H. Watson, K. J. Turner, J. Pastorek, A. Sibtain, G. D. Wilson, H. Turley, K. L. Talks and A. L. Harris, Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60, 7075-7083 (2000).
91. K. L. Talks, H. Turley, K. C. Gatter, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe and A. L. Harris, The expression and distribution of the hypoxia-inducible factors HIF-1 and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411-421 (2000).
92. H. Zhong, A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza and J. W. Simons, Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59, 5830-5835 (1999).
93. M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, C. Simopoulos, H. Turley, K. Talks, K. C. Gatter and A. L. Harris, Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radial. Oncol. Biol. Phys. 53, 1192-1202 (2002).
94. D. M. Aebersold, P. Burri, K. T. Beer, J. Laissue, V. Djonov, R. H. Greiner and G. L. Semenza, Expression of hypoxia-inducible factor-1α: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61, 2911-2916 (2001).
95. P. Birner, B. Gatterbauer, G. Oberhuber, M. Schindl, K. Rossler, A. Prodinger, H. Budka and J. A. Hainfellner, Expression of hypoxia-inducible factor-1α in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer 92, 165-171 (2001).
96. D. Vordermark and J. M. Brown, Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther. Onkol. 179, 801-811 (2003).
97. N. J. Beasley, R. Leek, M. Alam, H. Turley, G. J. Cox, K. Gatter, P. Millard, S. Fuggle and A. L. Harris, Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62, 2493-2497 (2002).
98. V. Vukovic, H. K. Haugland, T. Nicklee, A. J. Morrison and D. W. Hedley, Hypoxia-inducible factor-1α is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res. 61, 7394-7398 (2001).
99. D. Vordermark and J. M. Brown, Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: In vitro and xenograft studies. Int. J. Radiat. Oncol. Biol. Phys. 56, 1184-1193 (2003).
100. H. L. Janssen, K. M. Haustermans, D. Sprong, G. Blommestijn, I. Hofland, F. J. Hoebers, E. Blijweert, J. A. Raleigh, G. L. Semenza and A. C. Begg, HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 54, 1537-1549 (2002).
101. R. E. Airley, J. Loncaster, J. A. Raleigh, A. L. Harris, S. E. Davidson, R. D. Hunter, C. M. West and I. J. Stratford, GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. Int. J. Cancer 104, 85-91 (2003).
102. E. G. Troost, J. Bussink, J. H. Kaanders, J. van Eerd, J. P. Peters, P. F. Rijken, O. C. Boerman and A. J. van der Kogel, Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother. Oncol. 76, 194-199 (2005).
103. B. Jankovic, C. Aquino-Parsons, J. A. Raleigh, E. J. Stanbridge, R. E. Durand, J. P. Banath, S. H. MacPhail and P. L. Olive, Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin. Cytom. 70, 45-55 (2006).
104. P. L. Olive, C. Aquino-Parsons, S. H. MacPhail, S. Y. Liao, J. A. Raleigh, M. I. Lerman and E. J. Stanbridge, Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61, 8924-8929 (2001).
105. D. Vordermark, A. Kaffer, S. Riedl, A. Katzer and M. Flentje, Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 61, 1197-1207 (2005).
106. K. J. Turner, J. P. Crew, C. C. Wykoff, P. H. Watson, R. Poulsom, J. Pastorek, P. J. Ratcliffe, D. Cranston and A. L. Harris, The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br. J. Cancer 86, 1276-1282 (2002).
107. M. Rafajova, M. Zatovicova, R. Kettmann, J. Pastorek and S. Pastorekova, Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int. J. Oncol. 24, 995-1004 (2004).
108. B. S. Sorensen, J. Hao, J. Overgaard, H. Vorum, B. Honore, J. Alsner and M. R. Horsman, Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother. Oncol. 76, 187-193 (2005).
109. J. A. Loncaster, A. L. Harris, S. E. Davidson, J. P. Logue, R. D. Hunter, C. C. Wycoff, J. Pastorek, P. J. Ratcliffe, I. J. Stratford and C. M. West, Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61, 6394-6399 (2001).
110. M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. Simopoulos, J. Pastorek, C. C. Wykoff, K. C. Gatter and A. L. Harris, Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res. 7, 3399-3403 (2001).
111. D. Hedley, M. Pintilie, J. Woo, A. Morrison, D. Birle, A. Fyles, M. Milosevic and R. Hill, Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res. 9, 5666-5674 (2003).
112. R. A. Jonathan, K. I. Wijffels, W. Peeters, P. C. de Wilde, H. A. Marres, M. A. Merkx, E. Oosterwijk, A. J. van der Kogel and J. H. Kaanders, The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother. Oncol. 79, 288-297 (2006).
113. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12, 149-162 (1998).
114. M. Younes, D. Juarez, L. V. Lechago and S. P. Lerner, Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 21, 575-578 (2001).
115. M. Younes, R. W. Brown, M. Stephenson, M. Gondo and P. T. Cagle, Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80, 1046-1051 (1997).
116. R. S. Brown and R. L. Wahl, Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72, 2979-2985 (1993).
117. P. Mellanen, H. Minn, R. Grenman and P. Harkonen, Expression of glucose transporters in head-and-neck tumors. Int. J. Cancer 56, 622-629 (1994).
118. M. Younes, L. V. Lechago, J. R. Somoano, M. Mosharaf and J. Lechago, Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 56, 1164-1167 (1996).
119. R. S. Haber, A. Rathan, K. R. Weiser, A. Pritsker, S. H. Itzkowitz, C. Bodian, G. Slater, A. Weiss and D. E. Burstein, GLUT1 glucose transporter expression in colorectal carcinoma: A marker for poor prognosis. Cancer 83, 34-40 (1998).
120. R. Airley, J. Loncaster, S. Davidson, M. Bromley, S. Roberts, A. Patterson, R. Hunter, I. Stratford and C. West, Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res. 7, 928-934 (2001).
121. R. J. Oliver, R. T. Woodwards, P. Sloan, N. S. Thakker, I. J. Stratford and R. E. Airley, Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; Results of EORTC Translational Research Fund studies. Eur. J. Cancer 40, 503-507 (2004).
122. A. Mayer, M. Hockel, A. Wree and P. Vaupel, Microregional expression of glucose transporter-1 and oxygenation status: Lack of correlation in locally advanced cervical cancers. Clin. Cancer Res. 11, 2768-2773 (2005).
123. H. Mineta, K. Miura, S. Takebayashi, K. Misawa, K. Araki, Y. Misawa and Y. Ueda, Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res. 22, 3489-3494 (2002).
124. Y. Chen, G. Shi, W. Xia, C. Kong, S. Zhao, A. F. Gaw, E. Y. Chen, G. P. Yang, A. J. Giaccia and A. C. Koong, Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res. 64, 7302-7310 (2004).
125. S. C. Chou, Y. Azuma, M. A. Varia and J. A. Raleigh, Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br. J. Cancer 90, 728-735 (2004).
126. Q. T. Le, P. D. Sutphin, S. Raychaudhuri, S. C. Yu, D. J. Terris, H. S. Lin, B. Lum, H. A. Pinto, A. C. Koong and A. J. Giaccia, Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin. Cancer Res. 9, 59-67 (2003).
127. H. Nishi, K. H. Nishi and A. C. Johnson, Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res. 62, 827-834 (2002).
128. J. D. Blais, V. Filipenko, M. Bi, H. P. Harding, D. Ron, C. Koumenis, B. G. Wouters and J. C. Bell, Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol. Cell. Biol. 24, 7469-7482 (2004).
129. J. Overgaard, J. G. Eriksen, M. Nordsmark, J. Alsner and M. R. Horsman, Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 6, 757-764 (2005).
130. S. Nuyts, L. Van Mellaert, J. Theys, W. Landuyt, P. Lambin and J. Anne, Clostridium spores for tumor-specific drug delivery. Anticancer Drugs 13, 115-125 (2002).
131. I. Serganova and R. Blasberg, Reporter gene imaging: Potential impact on therapy. Nucl. Med. Biol. 32, 763-780 (2005).
132. G. E. Arteel, R. G. Thurman, J. M. Yates and J. A. Raleigh, Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 72, 889-895 (1995).
133. C. J. Koch, S. M. Evans and E. M. Lord, Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer 72, 869-874 (1995).
134. M. W. Gross, U. Karbach, K. Groebe, A. J. Franko and W. Mueller Klieser, Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int. J. Cancer 61, 567-573 (1995).
135. J. A. Raleigh, G. G. Miller, A. J. Franko, C. J. Koch, A. F. Fuciarelli and D. A. Kelly, Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br. J. Cancer 56, 395-400 (1987).
136. J. A. Raleigh, A. J. Franko, E. O. Treiber, J. A. Lunt and P. S. Allen, Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: Detection by F-19 nuclear magnetic resonance at 2.35 T. Int. J. Radiat. Oncol. Biol. Phys. 12, 1243-1245 (1986).
137. J. D. Chapman, A. J. Franko and J. Sharplin, A marker for hypoxic cells in tumours with potential clinical applicability. Br. J. Cancer 43, 546-550 (1981).
138. 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 12, 1263-1267 (1986).
139. 2 at the cellular level. Br. J. Cancer 54, 453-457 (1986).
140. L. M. Cobb, J. Nolan and S. A. Butler, Distribution of pimonidazole and RSU 1069 in tumour and normal tissues. Br. J. Cancer 62, 915-918 (1990).
141. K. M. Laughlin, S. M. Evans, W. T. Jenkins, M. Tracy, C. Y. Chan, E. M. Lord and C. J. Koch, Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J. Pharmacol. Exp. Ther. 277, 1049-1057 (1996).
142. 2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol. 41, 304-312 (2002).
143. C. J. Koch and S. M. Evans, Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv. Exp. Med. Biol. 510, 285-292 (2003).
144. S. M. Evans and C. J. Koch, Prognostic significance of tumor oxygenation in humans. Cancer Lett. 195, 1-16 (2003).
145. R. J. Hodgkiss, G. Jones, A. Long, J. Parrick, K. A. Smith, M. R. Stratford and G. D. Wilson, Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br. J. Cancer 63, 119-125 (1991).
146. D. E. Thrall, M. C. McEntee, J. M. Cline and J. A. Raleigh, ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation. Int. J. Radiat. Oncol. Biol. Phys. 28, 649-659 (1994).
147. C. Azuma, J. A. Raleigh and D. E. Thrall, Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat. Res. 148, 35-42 (1997).
148. R. E. Durand and J. A. Raleigh, Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 58, 3547-3550 (1998).
149. A. S. Kennedy, J. A. Raleigh, G. M. Perez, D. P. Calkins, D. E. Thrall, D. B. Novotny and M. A. Varia, Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys. 37, 897-905 (1997).
150. L. Webster, R. J. Hodgkiss and G. D. Wilson, Simultaneous triple staining for hypoxia, proliferation, and DNA content in murine tumours. Cytometry 21, 344-351 (1995).
151. J. Bussink, J. H. A. M. Kaanders, P. F. J. W. Rijken, J. A. Raleigh and A. J. Van der Kogel, Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat. Res. 153, 398-404 (2000).
152. P. F. J. W. Rijken, H. J. J. A. Bernsen, J. P. W. Peters, R. J. Hodgkiss, J. A. Raleigh and A. J. van der Kogel, Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: A quantitative multi-parameter analysis. Int. J. Radiat. Oncol. Biol. Phys. 48, 571-582 (2000).
153. A. S. E. Ljungkvist, J. Bussink, P. F. J. W. Rijken, J. A. Raleigh, J. Denekamp and A. J. van der Kogel, Changes in tumor hypoxia measured with a double hypoxic marker technique. Int. J. Radiat. Oncol. Biol. Phys. 48, 1529-1538 (2000).
154. A. S. E. Ljungkvist, J. Bussink, P. F. J. W. Rijken, J. A. Raleigh, J. H. A. M. Kaanders and A. J. van der Kogel, Hypoxic cell turnover in different solid lines. Int. J. Radiat. Oncol. Biol. Phys. 62, 1157-1168 (2005).
155. M. M. Kleiter, D. E. Thrall, D. E. Malarkey, X. Ji, D. Y. Lee, S. C. Chou and J. A. Raleigh, A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int. J. Radiat. Oncol. Biol. Phys. 64, 592-602 (2006).
156. J. S. Rasey, Z. Grunbaum, S. Magee, N. J. Nelson, P. L. Olive, R. E. Durand and K. A. Krohn, Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res. 111, 292-304 (1987).
157. J. A. Raleigh, A. J. Franko, C. J. Koch and J. L. Born, Binding of misonidazole to hypoxic cells in monolayer and spheroid culture: Evidence that a side-chain label is bound as efficiently as a ring label. Br. J. Cancer 51, 229-235 (1985).
158. A. J. Varghese, Glutathione conjugates of misonidazole. Biochem. Biophys. Res. Commun. 112, 1013-1020 (1983).
159. E. Chacon, C. J. Morrow, A. A. Leon, J. L. Born and B. R. Smith, Regioselective formation of a misonidazole-glutathione conjugate as a function of pH during chemical reduction. Biochem. Pharmacol. 37, 361-363 (1988).
160. J. A. Raleigh and C. J. Koch, Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 40, 2457-2464 (1990).
161. S. M. Evans, S. Hahn, D. R. Pook, W. T. Jenkins, A. A. Chalian, P. Zhang, C. Stevens, R. Weber, G. Weinstein and C. J. Koch, Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 60, 2018-2024 (2000).
162. M. A. Varia, D. P. Calkins Adams, L. H. Rinker, A. S. Kennedy, D. B. Novotny, W. C. Fowler, Jr. and J. A. Raleigh, Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol. Oncol. 71, 270-277 (1998).
163. K. Lehtio, O. Eskola, T. Viljanen, V. Oikonen, T. Gronroos, L. Sillanmaki, R. Grenman and H. Minn, Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 971-982 (2004).
164. 18FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl. Med. Biol. 30, 317-326 (2003).
165. 18F]FMISO in an experimental mammary carcinoma. Eur. J. Nucl. Med. Mol. Imaging 31, 513-520 (2004).
166. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J. Nucl. Med. 46, 253-260 (2005).
167. R. J. Hicks, D. Rischin, R. Fisher, D. Binns, A. M. Scott and L. J. Peters, Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur. J. Nucl. Med. Mol. Imaging 32, 1384-1391 (2005).
168. B. J. Krause, R. Beck, M. Souvatzoglou and M. Piert, PET and PET/CT studies of tumor tissue oxygenation. Q. J. Nucl. Med. Mol. Imaging 50, 28-43 (2006).
169. W. J. Koh, K. S. Bergman, J. S. Rasey, L. M. Peterson, M. L. Evans, M. M. Graham, J. R. Grierson, K. L. Lindsley, T. K. Lewellen and K. A. Krohn, Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 33, 391-398 (1995).
170. 18F]fluoromisonidazole: A pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 36, 417-428 (1996).
171. R. J. Hodgkiss, Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des. 13, 687-702 (1998).
172. R. J. Hodgkiss, M. R. Stratford, M. F. Dennis and S. A. Hill, Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: Effect of route of administration. Br. J. Cancer 72, 1462-1468 (1995).
173. E. M. Lord, L. Harwell and C. J. Koch, Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53, 5721-5726 (1993).
174. J. A. Raleigh, E. M. Zeman, M. Rathman, J. K. LaDine, J. M. Cline and D. E. Thrall, Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue. Int. J. Radiat. Oncol. Biol. Phys. 22, 403-405 (1992).
175. P. L. Olive, D. J. Chaplin and R. E. Durand, Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br. J. Cancer 52, 739-746 (1985).
176. J. A. Raleigh, S. C. Chou, D. P. Calkins Adams, C. A. Ballenger, D. B. Novotny and M. A. Varia, A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin. Cancer Res. 6, 855-862 (2000).
177. K. I. E. M. Wijffels, J. H. A. M. Kaanders, H. A. M. Marres, J. Bussink, H. P. W. Peters, P. F. J. W. Rijken, P. C. M. de Wilde and A. J. van der Kogel, Patterns of proliferation related to vasculature in human head-and-neck carcinomas before and after transplanatation in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 51, 1346-1353 (2001).
178. J. A. Raleigh, S. C. Chou, E. L. Bono, D. E. Thrall and M. A. Varia, Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int. J. Radiat. Oncol. Biol. Phys. 49, 569-574 (2001).
179. I. J. Hoogsteen, L. A. M. Pop, H. A. M. Marres, M. A. W. Merkx, F. J. A. van den Hoogen, A. J. van der Kogel and J. H. A. M. Kaanders, Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 64, 83-89 (2005).
180. J. A. Raleigh, S. C. Chou, G. E. Arteel and M. R. Horsman, Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat. Res. 151, 580-589 (1999).
181. M. Nordsmark, J. Loncaster, C. Aquino-Parsons, S. C. Chou, M. Ladekarl, H. Havsteen, J. C. Lindegaard, S. E. Davidson, M. Varia and J. A. Raleigh, Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother. Oncol. 67, 35-44 (2003).
182. M. Nordsmark, J. Loncaster, S. C. Chou, H. Havsteen, J. C. Lindegaard, S. E. Davidson, M. Varia, C. West, R. Hunter and J. A. Raleigh, Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 49, 581-586 (2001).
183. W. T. Jenkins, S. M. Evans and C. J. Koch, Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: Comparative measurements using EF5 binding and the Eppendorf needle electrode. Int. J. Radiat. Oncol. Biol. Phys. 46, 1005-1017 (2000).
184. J. Bussink, J. H. A. M. Kaanders, P. F. J. W. Rijken, J. P. W. Peters, R. J. Hodgkiss, H. A. Marres and A. J. van der Kogel, Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide. Radiother. Oncol. 50, 173-184 (1999).
185. J. Schuuring, J. Bussink, H. J. Bernsen, W. Peeters and A. J. van der Kogel, Irradiation combined with SU5416: Microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int. J. Radiat. Oncol. Biol. Phys. 61, 529-534 (2005).
186. K. A. Smith, S. A. Hill, A. C. Begg and J. Denekamp, Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br. J. Cancer 57, 247-253 (1988).
187. P. L. Olive and R. E. Durand, Characterization of a carbocyanine derivative as a fluorescent penetration probe. Cytometry 8, 571-575 (1987).
188. M. J. Trotter, D. J. Chaplin and P. L. Olive, Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br. J. Cancer 59, 706-709 (1989).
189. K. L. Bennewith and R. E. Durand, Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res. 64, 6183-6189 (2004).
190. R. V. Iyer, E. Kim, R. F. Schneider and J. D. Chapman, A dual hypoxic marker technique for measuring oxygenation change within individual tumors. Br. J. Cancer 78, 163-169 (1998).
191. H. W. M. van Laarhoven, J. Bussink, J. Lok, C. J. A. Punt, A. Heerschap and A. J. van der Kogel, Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters. Int. J. Radiat. Oncol. Biol. Phys. 60, 310-321 (2004).
192. A. S. E. Ljungkvist, J. Bussink, J. H. A. M. Kaanders, N. E. Wiedenmann, R. Vlasman and A. J. van der Kogel, Dynamics of hypoxia, proliferation and apoptosis in a murine tumor model after irradiation. Radiat. Res. 165, 326-336 (2006).
193. D. G. Hirst, J. Denekamp and B. Hobson, Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas. Cell. Tissue. Kinet. 15, 251-261 (1982).
194. R. E. Durand and E. Sham, The lifetime of hypoxic human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 42, 711-715 (1998).
195. G. E. Gifford, Some effects of anaerobiosis on the growth and metabolism of HeLa cells. Exp. Cell Res. 31, 113-118 (1962).
196. B. Littbrand and L. Revesz, Survival of cells in anoxia. Br. J. Radiol. 41, 479-480 (1968).
197. C. J. Koch, J. Kruuv and H. E. Frey, The effect of hypoxia on the generation time of mammalian cells. Radiat. Res. 53, 43-48 (1973).
198. C. J. Koch, J. Kruuv, H. E. Frey and R. A. Snyder, Plateau phase in growth induced by hypoxia. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 23, 67-74 (1973).
199. R. F. Kallman, The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105, 135-142 (1972).
200. P. L. Olive, Radiation-induced reoxygenation in the SCCVII murine tumour: Evidence for a decrease in oxygen consumption and an increase in tumour perfusion. Radiother. Oncol. 32, 37-46 (1994).
201. R. Murata, Y. Shibamoto, K. Sasai, N. Oya, T. Shibata, T. Takagi and M. Abe, Reoxygenation after single irradiation in rodent tumors of different types and sizes. Int. J. Radiat. Oncol. Biol. Phys. 34, 859-865 (1996).
202. I. H. Kim and J. M. Brown, Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int. J. Radiat. Oncol. Biol. Phys. 29, 493-497 (1994).
203. N. Crokart, B. F. Jordan, C. Baudelet, R. Ansiaux, O. Sonveuax, V. Gregoire, N. Begheon, J. d. Wever, C. Bouzin and B. Gallez, Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int. J. Radiat. Oncol. Biol. Phys. 63, 901-910 (2005).
204. J. D. Chapman, E. L. Engelhardt, C. C. Stobbe, R. F. Schneider and G. E. Hanks, Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother. Oncol. 46, 229-237 (1998).
205. A. J. Franko, C. J. Koch, B. M. Garrecht, J. Sharplin and D. Hughes, Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro. Cancer Res. 47, 5367-5376 (1987).
206. A. I. Minchinton and M. R. Stratford, A comparison of tumor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole radiosensitizers in mice. Int. J. Radiat. Oncol. Biol. Phys. 12, 1117-1120 (1986).
207. C. J. Koch, S. M. Hahn, K. Rockwell, Jr., J. M. Covey, W. G. McKenna and S. M. Evans, Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3, 3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother. Pharmacol. 48, 177-187 (2001).
208. J. D. Chapman, K. Baer and J. Lee, Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 43, 1523-1528 (1983).
209. L. Webster, R. J. Hodgkiss and G. D. Wilson, Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br. J. Cancer 77, 227-234 (1998).
210. R. J. Hodgkiss, L. Webster and G. D. Wilson, Measurement of hypoxia in vivo using a 2-nitroimidazole (NITP). Adv. Exp. Med. Biol. 428, 61-67 (1997).
211. J. M. Cline, D. E. Thrall, R. L. Page, A. J. Franko and J. A. Raleigh, Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br. J. Cancer 62, 925-931 (1990).
212. M. I. Saunders, P. J. Anderson, M. H. Bennett, S. Dische, A. Minchinton, M. R. Stratford and M. Tothill, The clinical testing of Ro 03-8799 - pharmacokinetics, toxicology, tissue and tumor concentrations. Int. J. Radiat. Oncol. Biol. Phys. 10, 1759-1763 (1984).
213. M. I. Walton, N. M. Bleehen and P. Workman, The reversible N-oxidation of the nitroimidazole radiosensitizer Ro 03-8799. Biochem. Pharmacol. 34, 3939-3940 (1985).
214. S. M. Evans, W. T. Jenkins, B. Joiner, E. M. Lord and C. J. Koch, 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res. 56, 405-411 (1996).
215. S. M. Evans, B. Joiner, W. T. Jenkins, K. M. Laughlin, E. M. Lord and C. J. Koch, Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br. J. Cancer 72, 875-882 (1995).